131I-hypericin

131I-hypericin (also known as OncoCiDia) is a targeted radiopharmaceutical therapy being developed by Oncocidia for the treatment of solid tumors. It consists of hypericin, a necrosis-avid small molecule, labeled with the radioactive isotope iodine-131. The therapeutic strategy, often referred to as OncoCiDia, involves a sequential dual-targeting approach: first, a vascular disrupting agent (such as combretastatin A-4 phosphate) or physical ablation (such as radiofrequency ablation or high-intensity focused ultrasound) is used to induce massive tumor necrosis. Subsequently, 131I-hypericin is administered, which selectively accumulates in the necrotic tumor tissue and delivers localized beta-radiation (and gamma-radiation for imaging) to destroy adjacent residual viable cancer cells. This approach is designed as an adjunct therapy to prevent tumor recurrence in primary and metastatic solid tumors.

Brand names

OncoCiDia

Other names

131I-monoiodohypericinIodine-131 labeled hypericinIodine131 labeled hypericinIodine 131 labeled hypericinIodine-131 labelled hypericinIodine131 labelled hypericinIodine 131 labelled hypericinradio-iodinated hypericinradioiodinated hypericin